Filing Flows › Aytu Biopharma (AYTU) › Guidance history
Aytu Biopharma (AYTU) guidance history: what it guided and what it reported
Aytu Biopharma gave guidance in 3 earnings releases on file since Nov 13, 2024.
Operating expenses
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY25 | $2.0M (Nov 13, 2024) → reaffirmed $2.0M (Feb 12, 2025) | — | — | — |
Adjusted EBITDA
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 FY27 | $500K (Sep 22, 2026) | — | to be reported | — |
The latest quarter
Aytu Biopharma, Q4 FY26: revenue $16.1M (+6% year over year), operating margin -4.8%, net loss $15K, operating cash flow $4.4M. The chart follows the revenue to costs, profit and cash.
Questions
Does Aytu Biopharma beat its guidance?
Aytu Biopharma gave guidance in 3 earnings releases on file since Nov 13, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.